Chemosensitivity testing of hematological cancers using ornithine decarboxylase as a marker

Y. Wang, R. Or, U. Bachrach

Research output: Contribution to journalArticlepeer-review


The in vitro chemosensitivities of lymphocytes and bone marrow specimens from hematological cancer patients have been examined. The tests were based on the quantitative immunohistochemical detection of ornithine decarboxylase. Ornithine decarboxylase catalyzes the rate limiting step of the biosynthesis of putrescine, an important member of the naturally occurring polyamines. This enzyme can be regarded as an early marker of proliferation and its presence in drug-treated cells suggests drug resistance, while its disappearance suggests drug-sensitivity. The validity of the concept has been confirmed first by testing the presence of ornithine decarboxylase in cultured cells, followed by testing blood samples from hematological cancer patients. It is conceivable that this in vitro chemosensitivity test can be applied for other malignacies.

Original languageEnglish (US)
Pages (from-to)51-56
Number of pages6
JournalInternational Journal of Medicine, Biology and the Environment
Issue number1
StatePublished - Dec 1 2000
Externally publishedYes


  • Anti-cancer drug
  • Bone-marrow
  • Chemosensitivity
  • Immunohistochemistry
  • Lymphocytes
  • Ornithine decarboxylase

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Fingerprint Dive into the research topics of 'Chemosensitivity testing of hematological cancers using ornithine decarboxylase as a marker'. Together they form a unique fingerprint.

Cite this